Literature DB >> 32991246

The Masquerading, Masculinizing Tumor: A Case Report and Review of the Literature.

Alexis LeVee1, Nissi Suppogu2, Christine Walsh3, Wendy Sacks4, James Simon5, Chrisandra Shufelt2.   

Abstract

Androgen-producing tumors in women are rare neoplasms that can cause secondary virilizing characteristics. Of patients presenting with symptoms of hyperandrogenism, these tumors are found in ∼0.2% of cases. Androgen-producing tumors can arise from the ovary or the adrenal gland. Those arising from the ovary are rare, accounting for <5% of all ovarian tumors. This case presents a hilar Leydig cell tumor of the ovary, which resulted in secondary virilization of a 45-year-old female 2 months after cessation of combined oral contraceptives (COC). Laboratory findings showed markedly elevated total and free testosterone concentrations with normal dehydroepiandrosterone sulfate, however neither pelvic ultrasound nor magnetic resonance imaging demonstrated any masses. Venous sampling under fluoroscopy revealed supraphysiologic testosterone concentrations from the right ovarian vein suggesting the source. The patient underwent bilateral salpingo-oophorectomy revealing a 1.3 cm hilar cell tumor of the right ovary. This article reviews the clinical features, diagnosis, and treatment of hilar Leydig cell tumors and describes the long-term complications of supraphysiologic testosterone levels. As the tumor presented after cessation of COC, we also review the mechanisms by which COC might suppress supraphysiologic androgen levels and mask the secondary virilizing effects of androgen-producing tumors.

Entities:  

Keywords:  HILAR cell tumor; Leydig cell; combined oral contraceptive; testosterone; virilization

Mesh:

Substances:

Year:  2020        PMID: 32991246      PMCID: PMC8290302          DOI: 10.1089/jwh.2020.8548

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   3.017


  27 in total

1.  Testosterone-producing ovarian tumor associated with erythrocytosis, hyperuricemia, and recurrent deep vein thrombosis.

Authors:  E K Muechler
Journal:  Am J Obstet Gynecol       Date:  1977-10-15       Impact factor: 8.661

2.  Long-term suppression of a testosterone-producing ovarian tumour by oestrogen/progestogen therapy.

Authors:  J O Drife; B P O'Malley; F D Rosenthal
Journal:  Clin Endocrinol (Oxf)       Date:  1987-07       Impact factor: 3.478

3.  Pure leydig cell tumour of the ovary in a post-menopausal patient with severe hyperandrogenism and erythrocytosis.

Authors:  Demet Ozgil Yetkin; Esra Terzi Demirsoy; Pinar Kadioglu
Journal:  Gynecol Endocrinol       Date:  2010-06-02       Impact factor: 2.260

4.  Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women.

Authors:  Gail A Laughlin; Vivian Goodell; Elizabeth Barrett-Connor
Journal:  J Clin Endocrinol Metab       Date:  2009-11-24       Impact factor: 5.958

Review 5.  Selective venous sampling for androgen-producing ovarian pathology.

Authors:  Eric D Levens; Brian W Whitcomb; John M Csokmay; Lynnette K Nieman
Journal:  Clin Endocrinol (Oxf)       Date:  2008-08-21       Impact factor: 3.478

6.  No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours.

Authors:  Carla Pelusi; Giulia Forlani; Laura Zanotti; Alessandra Gambineri; Renato Pasquali
Journal:  Clin Endocrinol (Oxf)       Date:  2013-04       Impact factor: 3.478

7.  Persistent Poor Metabolic Profile in Postmenopausal Women With Ovarian Hyperandrogenism After Testosterone Level Normalization.

Authors:  Thaís Rocha; Raiane P Crespo; Viviane V R Yance; Sylvia A Hayashida; Edmund C Baracat; Filomena Carvalho; Sorahia Domenice; Berenice B Mendonca; Larissa G Gomes
Journal:  J Endocr Soc       Date:  2019-04-04

Review 8.  The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis.

Authors:  Y Zimmerman; M J C Eijkemans; H J T Coelingh Bennink; M A Blankenstein; B C J M Fauser
Journal:  Hum Reprod Update       Date:  2013-09-29       Impact factor: 15.610

Review 9.  Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance.

Authors:  David J Handelsman; Angelica L Hirschberg; Stephane Bermon
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

10.  Global Consensus Position Statement on the Use of Testosterone Therapy for Women.

Authors:  Susan R Davis; Rodney Baber; Nicholas Panay; Johannes Bitzer; Sonia Cerdas Perez; Rakibul M Islam; Andrew M Kaunitz; Sheryl A Kingsberg; Irene Lambrinoudaki; James Liu; Sharon J Parish; JoAnn Pinkerton; Janice Rymer; James A Simon; Linda Vignozzi; Margaret E Wierman
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

View more
  2 in total

Review 1.  Recent Advances in the Clinical Application of Adrenal Vein Sampling.

Authors:  Shan Zhong; Tianyue Zhang; Minzhi He; Hanxiao Yu; Zhenjie Liu; Zhongyi Li; Xiaoxiao Song; Xiaohong Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-09       Impact factor: 5.555

2.  A rare ovarian hilus cell tumour accompanying bilateral serous cystadenomas: report of a case.

Authors:  Haider Ali Malakzai; Jamshid Abdul-Ghafar; Abdul Sami Ibrahimkhil; Ahmed Maseh Haidary
Journal:  J Ovarian Res       Date:  2021-06-21       Impact factor: 4.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.